Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2018 | Nov. 01, 2018 | |
Document Information [Line Items] | ||
Entity Registrant Name | Diffusion Pharmaceuticals Inc. | |
Entity Central Index Key | 1,053,691 | |
Trading Symbol | dffn | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Current Reporting Status | Yes | |
Entity Emerging Growth Company | false | |
Entity Small Business | true | |
Entity Common Stock, Shares Outstanding (in shares) | 50,643,429 | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2018 | |
Document Fiscal Year Focus | 2,018 | |
Document Fiscal Period Focus | Q3 | |
Amendment Flag | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Sep. 30, 2018 | Dec. 31, 2017 |
Current assets: | ||
Cash and cash equivalents | $ 11,018,441 | $ 8,896,468 |
Prepaid expenses, deposits and other current assets | 551,337 | 769,946 |
Total current assets | 11,569,778 | 9,666,414 |
Property and equipment, net | 379,202 | 460,652 |
Intangible asset | 8,639,000 | 8,639,000 |
Goodwill | 2,743,208 | 6,929,258 |
Other assets | 263,480 | 450,491 |
Total assets | 23,594,668 | 26,145,815 |
Current liabilities: | ||
Current portion of convertible debt | 550,000 | |
Accounts payable | 129,057 | 511,956 |
Accrued expenses and other current liabilities | 816,620 | 1,628,851 |
Total current liabilities | 945,677 | 2,690,807 |
Deferred income taxes | 1,741,253 | 2,223,678 |
Other liabilities | 1,386 | |
Total liabilities | 2,686,930 | 4,915,871 |
Commitments and Contingencies (Note 8) | ||
Convertible preferred stock, $0.001 par value: Series A - 13,750,000 shares authorized at both June 30, 2018 and December 31, 2017. No shares and 12,376,329 shares issued at June 30, 2018 and December 31, 2017, respectively. No shares and 8,306,278 shares outstanding at June 30, 2018 and December 31, 2017, respectively. | 0 | 0 |
Stockholders’ Equity: | ||
Common stock, $0.001 par value: 1,000,000,000 shares authorized; 50,572,001 and 14,519,629 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively. | 50,571 | 14,520 |
Additional paid-in capital | 95,210,928 | 82,770,313 |
Accumulated deficit | (74,353,761) | (61,554,889) |
Total stockholders' equity | 20,907,738 | 21,229,944 |
Total liabilities, convertible preferred stock and stockholders' equity | $ 23,594,668 | $ 26,145,815 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Sep. 30, 2018 | Dec. 31, 2017 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 0 | 13,750,000 |
Preferred stock, shares issued (in shares) | 0 | 12,376,329 |
Preferred stock, shares outstanding (in shares) | 0 | 8,306,278 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 1,000,000,000 | 1,000,000,000 |
Common stock, shares issued (in shares) | 50,572,001 | 14,519,629 |
Common stock, shares outstanding (in shares) | 50,572,001 | 14,519,629 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2018 | Sep. 30, 2017 | Sep. 30, 2018 | Sep. 30, 2017 | |
Operating expenses: | ||||
Research and development | $ 1,169,810 | $ 1,759,305 | $ 4,386,491 | $ 3,946,420 |
General and administrative | 1,589,621 | 1,559,399 | 4,748,090 | 4,908,424 |
Goodwill impairment | 4,186,050 | 4,186,050 | ||
Depreciation | 26,723 | 27,374 | 81,450 | 39,767 |
Loss from operations | 6,972,204 | 3,346,078 | 13,402,081 | 8,894,611 |
Other expense (income): | ||||
Interest (income) expense, net | (37,981) | (1,318) | (120,784) | 73,290 |
Change in fair value of warrant liability | (8,441,616) | (18,909,792) | ||
Warrant related expenses | 10,225,846 | |||
Other financing expenses | 2,870,226 | |||
(Loss) income from operations before income tax benefit | (6,934,223) | 5,096,856 | (13,281,297) | (3,154,181) |
Income tax benefit | (214,493) | (482,425) | ||
Net (loss) income | (6,719,730) | 5,096,856 | (12,798,872) | (3,154,181) |
Series A cumulative preferred dividends | (366,641) | (85,993) | (912,946) | |
Undistributed earnings to participating securities | (1,838,354) | |||
Deemed dividend related to the make-whole provision for the conversion of Series A convertible preferred stock into common stock | (8,167,895) | |||
Net (loss) income attributable to common stockholders | $ (6,719,730) | $ 2,891,861 | $ (21,052,760) | $ (4,067,127) |
Per share information: | ||||
Net (loss) income per share of common stock, basic (in dollars per share) | $ (0.13) | $ 0.21 | $ (0.44) | $ (0.35) |
Net (loss) income per share of common stock, diluted (in dollars per share) | $ (0.13) | $ 0.20 | $ (0.44) | $ (1.83) |
Weighted average shares outstanding, basic (in shares) | 50,572,001 | 13,937,869 | 47,777,757 | 11,709,128 |
Weighted average shares outstanding, diluted (in shares) | 50,572,001 | 14,714,853 | 47,777,757 | 12,525,707 |
Condensed Consolidated Statem_2
Condensed Consolidated Statement of Changes in Convertible Preferred Stock and Stockholders' Equity (Unaudited) - 9 months ended Sep. 30, 2018 - USD ($) | Preferred Stock [Member]Series A Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Series A Preferred Stock [Member] | Total |
Balance (in shares) at Dec. 31, 2017 | 8,306,278 | 14,519,629 | ||||
Balance at Dec. 31, 2017 | $ 14,520 | $ 82,770,313 | $ (61,554,889) | $ 21,229,944 | ||
Conversion of Series A convertible preferred stock to common stock (in shares) | (8,306,278) | 8,306,278 | ||||
Conversion of Series A convertible preferred stock to common stock | $ 8,306 | (8,306) | ||||
Issuance of common stock to Series A convertible preferred stockholders under make-whole adjustment feature | $ 11,668 | (11,668) | ||||
Issuance of common stock to Series A convertible preferred stockholders under make-whole adjustment feature (in shares) | 11,668,421 | |||||
Issuance of common stock related to accrued dividends | $ 1,032 | 1,147,275 | 1,148,307 | |||
Issuance of common stock related to accrued dividends (in shares) | 1,032,219 | |||||
Series A cumulative preferred dividends | (85,993) | $ (85,993) | (85,993) | |||
Issuance of common stock and warrants, net of issuance costs | $ 15,000 | 10,402,520 | 10,417,520 | |||
Issuance of common stock and warrants, net of issuance costs (in shares) | 15,000,000 | |||||
Common stock issued for advisory services | $ 45 | 24,955 | 25,000 | |||
Common stock issued for advisory services (in shares) | 45,454 | |||||
Stock-based compensation expense | 971,832 | 971,832 | ||||
Net loss | (12,798,872) | (12,798,872) | ||||
Balance (in shares) at Sep. 30, 2018 | 50,572,001 | |||||
Balance at Sep. 30, 2018 | $ 50,571 | $ 95,210,928 | $ (74,353,761) | $ 20,907,738 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 9 Months Ended | |
Sep. 30, 2018 | Sep. 30, 2017 | |
Operating activities: | ||
Net loss | $ (12,798,872) | $ (3,154,181) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation | 81,450 | 39,767 |
Stock-based compensation expense | 971,832 | 973,950 |
Common stock issued for advisory services | 25,000 | 50,000 |
Warrant related expense, change in fair value, and other financing expenses | (5,813,720) | |
Change in deferred income taxes | (482,425) | |
Goodwill impairment | 4,186,050 | |
Non-cash interest expense | 11,967 | |
Changes in operating assets and liabilities: | ||
Prepaid expenses, deposits and other assets | 405,620 | (661,675) |
Accounts payable, accrued expenses and other liabilities | (134,202) | (1,496,150) |
Net cash used in operating activities | (7,745,547) | (10,050,042) |
Cash flows used in investing activities: | ||
Purchases of property and equipment | (438,604) | |
Purchase of certificate of deposit | (10,000,000) | |
Net cash used in investing activities | (10,438,604) | |
Cash flows provided by financing activities: | ||
Repayment of convertible debt principal | (550,000) | (1,880,000) |
Proceeds from the sale of common stock | 10,846,062 | |
Proceeds from the sale of Series A convertible preferred stock, net | 22,129,774 | |
Payment of offering costs | (428,542) | (97,980) |
Net cash provided by financing activities | 9,867,520 | 20,151,794 |
Net increase (decrease) in cash and cash equivalents | 2,121,973 | (336,852) |
Cash and cash equivalents at beginning of period | 8,896,468 | 1,552,852 |
Cash and cash equivalents at end of period | 11,018,441 | 1,216,000 |
Supplemental disclosure of cash flow information | ||
Cash paid for interest | 40,142 | 112,800 |
Supplemental disclosure of non-cash investing and financing activities: | ||
Reclassification of accrued dividends related to the issuance of common stock to Series A convertible preferred stock holders | 1,148,307 | |
Series A cumulative preferred dividends | (85,993) | |
Conversion of accrued dividends related to Series A convertible preferred stock | 187,172 | |
Series A Preferred Stock [Member] | ||
Supplemental disclosure of non-cash investing and financing activities: | ||
Series A cumulative preferred dividends | $ (85,993) | $ (912,946) |
Note 1 - Organization and Descr
Note 1 - Organization and Description of Business | 9 Months Ended |
Sep. 30, 2018 | |
Notes to Financial Statements | |
Nature of Operations [Text Block] | 1. Organization and Description of Business Diffusion Pharmaceuticals Inc. (“Diffusion” or the “Company”), a Delaware corporation, is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The Company is developing its lead product candidate, trans sodium crocetinate (“TSC”) for use in many cancer types in which tumor oxygen deprivation ("hypoxia") is known to diminish the effectiveness of current treatments. TSC is designed to target the cancer’s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells more susceptible to the therapeutic effects of standard-of-care radiation therapy and chemotherapy. Other possible uses of TSC include the treatment of hypoxic conditions such as stroke, cardiovascular disease, neurodegenerative disease and emergency medicine. |
Note 2 - Liquidity
Note 2 - Liquidity | 9 Months Ended |
Sep. 30, 2018 | |
Notes to Financial Statements | |
Liquidity [Text Block] | 2. Liquidity The Company has not No The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third January 22, 2018, 15,000,000 $0.001 15,000,000 1,970,625 $0.80 $10.8 $0.80 five 750,000 $1.00, five 21,006,918 The Company currently does not may March 2, 2018, not 5550 2 $1.00 30 5810 3 180 August 29, 2018, $1.00 10 August 30, 2018, not August 29, 2018, 5810 3 180 February 25, 2019, In the event the Company is unable to regain compliance, it could adversely affect the Company’s ability to obtain future funding. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with third may not 2018 June 14, 2018, not 1 2 not 1 15, The Company has prepared its financial statements assuming that it will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its potential product candidates, which raises substantial doubt about the Company’s ability to continue as a going concern. The Company currently has no may not not Operations of the Company are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when the Company’s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company’s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company’s financial condition and future operations. The Company believes its cash and cash equivalents at September 30, 2018 September 2019. |
Note 3 - Basis of Presentation
Note 3 - Basis of Presentation and Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2018 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 3. Basis of Presentation and Summary of Significant Accounting Policies The Summary of Significant Accounting Policies included in the Company's Form 10 December 31, 2017, April 2, 2018 not Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as found in the Accounting Standard Codification (“ASC”) and Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”), and with the instructions to Form 10 10 X September 30, 2018, three nine September 30, 2018 2017 nine September 30, 2018 2017. nine September 30, 2018 not may December 31, 2018. not December 31, 2017 10 April 2, 2018. Use of Estimates The preparation of the unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date the financial statements and reported amounts of expense during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited interim condensed consolidated financial statements, actual results may Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. As of December 31, 2017, $0.6 3 Convertible Debt Upon maturity of the Series B convertible debt during the second 2018, $0.6 $40,000, not September 30, 2018. Intangible Asset and Goodwill Goodwill and intangible assets deemed to have indefinite lives are not may not January 2017, December 15, 2019, 529 October 1 no 529 three nine September 30, 2018 2017. three September 30, 2018, $4.2 5 Income Taxes On December 22, 2017 2017 2017 21% 34% January 1, 2018 2018 three nine September 30, 2018, $0.2 $0.5 2017 Net (Loss) Income Per Common Share For the three nine September 30, 2017, two two not no Diluted net (loss) income per common share is computed under the two two For the periods in which the Company reported a net loss, there was no two three September 30, 2017, two For purposes of calculating diluted loss per common share, the denominator includes both the weighted average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include stock options, unvested restricted stock awards and warrants using the treasury stock method. The diluted loss per common share calculation is further affected by an add-back of change in fair value of warrant liability to the numerator under the assumption that the change in fair value of warrant liability would not The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Basic net (loss) income per common share calculation: Net (loss) income $ (6,719,730 ) $ 5,096,856 $ (12,798,872 ) $ (3,154,181 ) Accretion of Series A cumulative preferred dividends — (366,641 ) (85,993 ) (912,946 ) Undistributed earnings allocated to participating securities — (1,838,354 ) Deemed dividend related to the make-whole provision for the conversion of Series A preferred stock into common — — (8,167,895 ) — Net (loss) income attributable to common (6,719,730 ) 2,891,861 (21,052,760 ) (4,067,127 ) Weighted average common shares outstanding, basic 50,572,001 13,937,869 47,777,757 11,709,128 Net (loss) income per share of common, basic $ (0.13 ) $ 0.21 $ (0.44 ) $ (0.35 ) Diluted net income (loss) per common share calculation: Net income (loss) attributable to common (6,719,730 ) 2,891,861 (21,052,760 ) (4,067,127 ) Change in fair value of warrant liability — — — (18,909,792 ) Interest on convertible debt — 28,891 — — Diluted net loss (6,719,730 ) 2,920,752 (21,052,760 ) (22,976,919 ) Weighted average common shares outstanding, basic 50,572,001 13,937,869 47,777,757 11,709,128 Common stock equivalents arising from stock options — 20,608 — — Common stock equivalents arising from warrants — — — 816,579 Common stock equivalents arising from convertible debt — 756,376 — — Common stock equivalents 50,572,001 14,714,853 47,777,757 12,525,707 Diluted net loss per share of common $ (0.13 ) $ 0.20 $ (0.44 ) $ (1.83 ) The following potentially dilutive securities outstanding as of September 30, 2018 2017 Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Convertible debt — — — 213,879 Common stock warrants 31,303,012 14,003,608 31,303,012 447,721 Stock options 3,213,797 2,521,605 3,213,797 2,545,989 Unvested restricted stock awards — 4,599 — 4,599 34,516,809 16,529,812 34,516,809 3,212,188 Amounts in the table reflect the common stock equivalents of the noted instruments. As a result of the offering of its common stock consummated in January 2018, 6 Recent Accounting Pronouncements In August 2018, 2018 03, Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurements, 820. 820's December 15, 2019 In June 2018, 2018 07, Improvements to Nonemployee Share-Based Accounting, 505 50 718 all 718 2018 07 1 not 2 not December 15, 2019 In July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 first second December 15, 2018 In January 2017, 2017 04, Intangibles-Goodwill and Other (Topic 350 2 December 15, 2019, January 1, 2017, January 1, 2017. third 2018. 5 In February 2016, 2016 02, Leases (Topic 842 840, Leases 842 January 1, 2019, 8 842 842 not |
Note 4 - Accrued Expenses and O
Note 4 - Accrued Expenses and Other Current Liabilities | 9 Months Ended |
Sep. 30, 2018 | |
Notes to Financial Statements | |
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] | 4. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: September 30, 2018 December 31, 2017 Accrued interest payable $ — $ 37,415 Accrued Series A dividends — 1,062,314 Accrued payroll and payroll related expenses 618,131 312,221 Accrued professional fees 80,051 122,711 Accrued clinical studies expenses 47,688 63,350 Other accrued expenses 70,750 30,840 Total $ 816,620 $ 1,628,851 |
Note 5 - Goodwill and Intangibl
Note 5 - Goodwill and Intangible Assets | 9 Months Ended |
Sep. 30, 2018 | |
Notes to Financial Statements | |
Goodwill and Intangible Assets Disclosure [Text Block] | 5. Goodwill and Intangible Assets Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. The Company applies ASC 350 Goodwill and Other Intangible Assets October 1 third may not three September 30, 2018. Management performed the goodwill impairment assessment using a market approach to estimate the fair value of the Company using the Company's market capitalization. This fair value was derived by multiplying the Company's shares outstanding by the average daily close prices of the Company's stock during the third $4.2 nine September 30, 2018: Carrying value of goodwill at December 31, 2017: $ 6,929,258 Impairment of goodwill (4,186,050 ) Carrying value of goodwill at September 30, 2018: $ 2,743,208 The Company has an indefinite-lived In-Process Research and Development Asset (IPR&D) called RES- 529, $8.6 September 30, 2018 December 31, 2017. 529 PI3K/Akt/mTOR no 529 three nine September 30, 2018 2017. |
Note 6 - Convertible Preferred
Note 6 - Convertible Preferred Stock, Common Stock and Common Stock Warrants | 9 Months Ended |
Sep. 30, 2018 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 6. Convertible Preferred Stock, Common Stock and Common Stock Warrants 2018 In January 2018, 15,000,000 15,000,000 $0.80 $10.8 2,250,000 2,250,000 1,970,625 $0.80 In addition, at the closing, the Company issued to designees of the underwriter warrants to purchase up to 750,000 $1.00 five During its evaluation of equity classification for the Common Stock warrants, the Company considered the conditions as prescribed within ASC 815 40, Derivatives and Hedging, Contracts in an Entity’s own Equity 815 40” 815 40 not not 480 Distinguishing Liabilities from Equity not not 815, As a result of the Company's Common Stock offering in January 2018, 21,006,918 8,306,278 1,032,219 11,668,421 $8.2 Common Stock Warrants As of September 30, 2018, Outstanding Range of exercise price per share Expiration dates Common stock warrants issued prior to 2016 26,500 $37.50 - $49.00 2018 through 2019 Common stock warrants issued related to Series A convertible preferred stock offering 13,555,887 $2.22 March 2022 Common stock warrants issued in 2018 related to the common stock offering 17,720,625 $0.80 - $1.00 January 2023 31,303,012 During the nine September 30, 2018, 421,221 no |
Note 7 - Stock-based Compensati
Note 7 - Stock-based Compensation | 9 Months Ended |
Sep. 30, 2018 | |
Notes to Financial Statements | |
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | 7. Stock-Based Compensation 2015 The Diffusion Pharmaceuticals Inc. 2015 "2015 January 1, 4.0% December 31, 580,785 January 1, 2018, may 2015 September 30, 2018, 27,268 2015 The Company recorded stock-based compensation expense in the following expense categories of its unaudited interim condensed consolidated statements of operations for the periods indicated: Three Months Ended September 30, Nine Months Ended 2018 2017 2018 2017 Research and development $ 16,202 $ 14,333 $ 48,848 $ 81,737 General and administrative 311,194 278,168 922,984 892,213 Total stock-based compensation expense $ 327,396 $ 292,501 $ 971,832 $ 973,950 The following table summarizes the activity related to all stock option grants to employees and non-employees for the nine September 30, 2018: Number of Options Weighted average exercise price per share Weighted average remaining contractual life (in years) Balance at January 1, 2018 2,555,989 $ 7.32 Granted 660,000 1.02 Expired (2,192 ) 17.10 Outstanding at September 30, 2018 3,213,797 $ 6.02 7.01 Exercisable at September 30, 2018 2,361,007 $ 7.09 6.35 Non-employee Stock Options Non-employee stock options are remeasured to fair value each period using a Black-Scholes option-pricing model until the options vest. The Company did not nine September 30, 2018. three September 30, 2018 2017 $1,000 $7,000, nine September 30, 2018 2017 $3,000 $83,000, September 30, 2018, 5,166 $2,000 1.26 Employee Stock Options During the nine September 30, 2018, 660,000 $0.86 nine September 30, 2018. three September 30, 2018 2017 $0.3 $0.3 nine September 30, 2018 2017, $1.0 $0.9 No September 30, 2018, $2.1 5.2 Options granted were valued using the Black-Scholes option-pricing model and the weighted average assumptions used to value the options granted during the nine September 30, 2018 2017 2018 2017 Expected term (in years) 5.57 6.03 Risk-free interest rate 2.4 % 2.0 % Expected volatility 114.7 % 114.9 % Dividend yield — % — % Restricted Stock Awards As of September 30, 2018, no nine September 30, 2018 2017, 3,066 4,599 $6,000 $9,000, |
Note 8 - Commitments and Contin
Note 8 - Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2018 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 8. Commitments and Contingencies Office Space Rental The Company leases office and laboratory facilities in Charlottesville, Virginia. Rent expense related to the Company's operating lease for the three September 30, 2018 2017 $28,000 $28,000, nine September 30, 2018 2017 $84,000 $80,000, not September 30, 2018 Rental Commitments 2018 $ 28,260 2019 114,409 2020 116,464 2021 118,519 2022 39,735 Total $ 417,387 Arrangement with Clinical Research Organization On July 5, 2017, $0.4 $1.6 three nine September 30, 2018. September 30, 2018, $0.3 2018. Legal Proceedings On August 7, 2014, Paul Feller v. RestorGenex Corporation, Pro Sports & Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH No. BC553996 December 30, 2014, April 1, 2015, April 14, 2015, January 8, 2016, No November 19, 2018. may |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2018 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as found in the Accounting Standard Codification (“ASC”) and Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”), and with the instructions to Form 10 10 X September 30, 2018, three nine September 30, 2018 2017 nine September 30, 2018 2017. nine September 30, 2018 not may December 31, 2018. not December 31, 2017 10 April 2, 2018. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of the unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date the financial statements and reported amounts of expense during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited interim condensed consolidated financial statements, actual results may |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. As of December 31, 2017, $0.6 3 |
Debt, Policy [Policy Text Block] | Convertible Debt Upon maturity of the Series B convertible debt during the second 2018, $0.6 $40,000, not September 30, 2018. |
Goodwill and Intangible Assets, Policy [Policy Text Block] | Intangible Asset and Goodwill Goodwill and intangible assets deemed to have indefinite lives are not may not January 2017, December 15, 2019, 529 October 1 no 529 three nine September 30, 2018 2017. three September 30, 2018, $4.2 5 |
Income Tax, Policy [Policy Text Block] | Income Taxes On December 22, 2017 2017 2017 21% 34% January 1, 2018 2018 three nine September 30, 2018, $0.2 $0.5 2017 |
Earnings Per Share, Policy [Policy Text Block] | Net (Loss) Income Per Common Share For the three nine September 30, 2017, two two not no Diluted net (loss) income per common share is computed under the two two For the periods in which the Company reported a net loss, there was no two three September 30, 2017, two For purposes of calculating diluted loss per common share, the denominator includes both the weighted average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include stock options, unvested restricted stock awards and warrants using the treasury stock method. The diluted loss per common share calculation is further affected by an add-back of change in fair value of warrant liability to the numerator under the assumption that the change in fair value of warrant liability would not The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Basic net (loss) income per common share calculation: Net (loss) income $ (6,719,730 ) $ 5,096,856 $ (12,798,872 ) $ (3,154,181 ) Accretion of Series A cumulative preferred dividends — (366,641 ) (85,993 ) (912,946 ) Undistributed earnings allocated to participating securities — (1,838,354 ) Deemed dividend related to the make-whole provision for the conversion of Series A preferred stock into common — — (8,167,895 ) — Net (loss) income attributable to common (6,719,730 ) 2,891,861 (21,052,760 ) (4,067,127 ) Weighted average common shares outstanding, basic 50,572,001 13,937,869 47,777,757 11,709,128 Net (loss) income per share of common, basic $ (0.13 ) $ 0.21 $ (0.44 ) $ (0.35 ) Diluted net income (loss) per common share calculation: Net income (loss) attributable to common (6,719,730 ) 2,891,861 (21,052,760 ) (4,067,127 ) Change in fair value of warrant liability — — — (18,909,792 ) Interest on convertible debt — 28,891 — — Diluted net loss (6,719,730 ) 2,920,752 (21,052,760 ) (22,976,919 ) Weighted average common shares outstanding, basic 50,572,001 13,937,869 47,777,757 11,709,128 Common stock equivalents arising from stock options — 20,608 — — Common stock equivalents arising from warrants — — — 816,579 Common stock equivalents arising from convertible debt — 756,376 — — Common stock equivalents 50,572,001 14,714,853 47,777,757 12,525,707 Diluted net loss per share of common $ (0.13 ) $ 0.20 $ (0.44 ) $ (1.83 ) The following potentially dilutive securities outstanding as of September 30, 2018 2017 Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Convertible debt — — — 213,879 Common stock warrants 31,303,012 14,003,608 31,303,012 447,721 Stock options 3,213,797 2,521,605 3,213,797 2,545,989 Unvested restricted stock awards — 4,599 — 4,599 34,516,809 16,529,812 34,516,809 3,212,188 Amounts in the table reflect the common stock equivalents of the noted instruments. As a result of the offering of its common stock consummated in January 2018, 6 |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements In August 2018, 2018 03, Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurements, 820. 820's December 15, 2019 In June 2018, 2018 07, Improvements to Nonemployee Share-Based Accounting, 505 50 718 all 718 2018 07 1 not 2 not December 15, 2019 In July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 first second December 15, 2018 In January 2017, 2017 04, Intangibles-Goodwill and Other (Topic 350 2 December 15, 2019, January 1, 2017, January 1, 2017. third 2018. 5 In February 2016, 2016 02, Leases (Topic 842 840, Leases 842 January 1, 2019, 8 842 842 not |
Note 3 - Basis of Presentatio_2
Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables) | 9 Months Ended |
Sep. 30, 2018 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Basic net (loss) income per common share calculation: Net (loss) income $ (6,719,730 ) $ 5,096,856 $ (12,798,872 ) $ (3,154,181 ) Accretion of Series A cumulative preferred dividends — (366,641 ) (85,993 ) (912,946 ) Undistributed earnings allocated to participating securities — (1,838,354 ) Deemed dividend related to the make-whole provision for the conversion of Series A preferred stock into common — — (8,167,895 ) — Net (loss) income attributable to common (6,719,730 ) 2,891,861 (21,052,760 ) (4,067,127 ) Weighted average common shares outstanding, basic 50,572,001 13,937,869 47,777,757 11,709,128 Net (loss) income per share of common, basic $ (0.13 ) $ 0.21 $ (0.44 ) $ (0.35 ) Diluted net income (loss) per common share calculation: Net income (loss) attributable to common (6,719,730 ) 2,891,861 (21,052,760 ) (4,067,127 ) Change in fair value of warrant liability — — — (18,909,792 ) Interest on convertible debt — 28,891 — — Diluted net loss (6,719,730 ) 2,920,752 (21,052,760 ) (22,976,919 ) Weighted average common shares outstanding, basic 50,572,001 13,937,869 47,777,757 11,709,128 Common stock equivalents arising from stock options — 20,608 — — Common stock equivalents arising from warrants — — — 816,579 Common stock equivalents arising from convertible debt — 756,376 — — Common stock equivalents 50,572,001 14,714,853 47,777,757 12,525,707 Diluted net loss per share of common $ (0.13 ) $ 0.20 $ (0.44 ) $ (1.83 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Convertible debt — — — 213,879 Common stock warrants 31,303,012 14,003,608 31,303,012 447,721 Stock options 3,213,797 2,521,605 3,213,797 2,545,989 Unvested restricted stock awards — 4,599 — 4,599 34,516,809 16,529,812 34,516,809 3,212,188 |
Note 4 - Accrued Expenses and_2
Note 4 - Accrued Expenses and Other Current Liabilities (Tables) | 9 Months Ended |
Sep. 30, 2018 | |
Notes Tables | |
Other Current Liabilities [Table Text Block] | September 30, 2018 December 31, 2017 Accrued interest payable $ — $ 37,415 Accrued Series A dividends — 1,062,314 Accrued payroll and payroll related expenses 618,131 312,221 Accrued professional fees 80,051 122,711 Accrued clinical studies expenses 47,688 63,350 Other accrued expenses 70,750 30,840 Total $ 816,620 $ 1,628,851 |
Note 5 - Goodwill and Intangi_2
Note 5 - Goodwill and Intangible Assets (Tables) | 9 Months Ended |
Sep. 30, 2018 | |
Notes Tables | |
Schedule of Goodwill [Table Text Block] | Carrying value of goodwill at December 31, 2017: $ 6,929,258 Impairment of goodwill (4,186,050 ) Carrying value of goodwill at September 30, 2018: $ 2,743,208 |
Note 6 - Convertible Preferre_2
Note 6 - Convertible Preferred Stock, Common Stock and Common Stock Warrants (Tables) | 9 Months Ended |
Sep. 30, 2018 | |
Notes Tables | |
Schedule of Warrants Outstanding to Acquire Shares of Common Stock [Table Text Block] | <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 44%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Range of exercise price per share</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 16%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Expiration dates</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued prior to 2016</div> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,500</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$37.50</div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$49.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 16%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018 through 2019</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to Series A convertible preferred stock offering</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,555,887</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.22</div></td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 16%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">March 2022</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in 2018 related to the common stock offering</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,720,625</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.80</div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 16%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">January 2023</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,303,012</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 16%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> </table></div>" id="sjs-B4"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 44%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Range of exercise price per share</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 16%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Expiration dates</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued prior to 2016</div> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,500</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$37.50</div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$49.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 16%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018 through 2019</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to Series A convertible preferred stock offering</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,555,887</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.22</div></td> <td style="width: 4%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 16%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">March 2022</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in 2018 related to the common stock offering</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,720,625</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.80</div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 16%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">January 2023</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,303,012</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 16%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> </table></div> |
Note 7 - Stock-based Compensa_2
Note 7 - Stock-based Compensation (Tables) | 9 Months Ended |
Sep. 30, 2018 | |
Notes Tables | |
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] | Three Months Ended September 30, Nine Months Ended 2018 2017 2018 2017 Research and development $ 16,202 $ 14,333 $ 48,848 $ 81,737 General and administrative 311,194 278,168 922,984 892,213 Total stock-based compensation expense $ 327,396 $ 292,501 $ 971,832 $ 973,950 |
Share-based Compensation, Stock Options, Activity [Table Text Block] | Number of Options Weighted average exercise price per share Weighted average remaining contractual life (in years) Balance at January 1, 2018 2,555,989 $ 7.32 Granted 660,000 1.02 Expired (2,192 ) 17.10 Outstanding at September 30, 2018 3,213,797 $ 6.02 7.01 Exercisable at September 30, 2018 2,361,007 $ 7.09 6.35 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | 2018 2017 Expected term (in years) 5.57 6.03 Risk-free interest rate 2.4 % 2.0 % Expected volatility 114.7 % 114.9 % Dividend yield — % — % |
Note 8 - Commitments and Cont_2
Note 8 - Commitments and Contingencies (Tables) | 9 Months Ended |
Sep. 30, 2018 | |
Notes Tables | |
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] | Rental Commitments 2018 $ 28,260 2019 114,409 2020 116,464 2021 118,519 2022 39,735 Total $ 417,387 |
Note 2 - Liquidity (Details Tex
Note 2 - Liquidity (Details Textual) $ / shares in Units, $ in Millions | Jun. 14, 2018 | Jan. 22, 2018USD ($)$ / sharesshares | Jan. 31, 2018USD ($)$ / sharesshares | Sep. 30, 2018$ / shares | Dec. 31, 2017$ / shares |
Common Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 | $ 0.001 | ||
Conversion From Series A Preferred Stock to Common Stock [Member] | |||||
Conversion of Stock, Shares Issued | shares | 21,006,918 | 21,006,918 | |||
Maximum [Member] | Reverse Stock Split [Member ] | |||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 15 | ||||
Minimum [Member] | Reverse Stock Split [Member ] | |||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 2 | ||||
Warrants Issued in Connection with the January 2018 Offering [Member] | |||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 15,000,000 | 15,000,000 | |||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.80 | $ 0.80 | |||
Class of Warrant or Right, Term | 5 years | ||||
Warrants Issued in Connection with the January 2018 Offering [Member] | Maximum [Member] | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | 1 | ||||
Warrants Issued in Connection with the January 2018 Offering [Member] | Minimum [Member] | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.80 | ||||
Additional Warrants [Member] | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | 0.80 | ||||
Underwriter Warrants [Member] | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1 | ||||
Underwriter Warrants [Member] | H.C Wainwright & Co., LLC [Member] | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1 | ||||
Class of Warrant or Right, Term | 5 years | ||||
Underwriter Warrants [Member] | Maximum [Member] | |||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 750,000 | 750,000 | |||
Class of Warrant or Right, Term | 5 years | ||||
January 2018 Offering [Member] | |||||
Stock Issued During Period, Shares, New Issues | shares | 15,000,000 | 15,000,000 | |||
Share Price | $ 0.80 | ||||
Proceeds from Issuance or Sale of Equity, Total | $ | $ 10.8 | $ 10.8 | |||
January 2018 Offering [Member] | Additional Warrants [Member] | |||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 1,970,625 |
Note 3 - Basis of Presentatio_3
Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2018 | Sep. 30, 2017 | Jun. 30, 2018 | Sep. 30, 2018 | Sep. 30, 2017 | Dec. 31, 2017 | |
Repayments of Long-term Debt, Total | $ 550,000 | $ 1,880,000 | ||||
Interest Paid, Excluding Capitalized Interest, Operating Activities | 40,142 | 112,800 | ||||
Impairment of Intangible Assets (Excluding Goodwill), Total | $ 0 | $ 0 | 0 | 0 | ||
Goodwill, Impairment Loss | 4,186,050 | $ 4,186,050 | ||||
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 21.00% | 34.00% | ||||
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability | 200,000 | $ 500,000 | ||||
Convertible Note, Series B [Member] | ||||||
Repayments of Long-term Debt, Total | $ 600,000 | |||||
Interest Paid, Excluding Capitalized Interest, Operating Activities | $ 40,000 | |||||
Convertible Debt, Total | $ 0 | $ 0 | ||||
Fair Value, Inputs, Level 3 [Member] | Convertible Note, Series B [Member] | ||||||
Convertible Debt, Fair Value Disclosures | $ 600,000 |
Note 3 - Basis of Presentatio_4
Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Basic and Diluted Earnings Per Share (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2018 | Sep. 30, 2017 | Sep. 30, 2018 | Sep. 30, 2017 | |
Net (loss) income | $ (6,719,730) | $ 5,096,856 | $ (12,798,872) | $ (3,154,181) |
Accretion of Series A cumulative preferred dividends | (366,641) | (85,993) | (912,946) | |
Undistributed earnings to participating securities | (1,838,354) | |||
Deemed dividend related to the make-whole provision for the conversion of Series A preferred stock into common | (8,167,895) | |||
Net (loss) income attributable to common | $ (6,719,730) | $ 2,891,861 | $ (21,052,760) | $ (4,067,127) |
Weighted average shares outstanding, basic (in shares) | 50,572,001 | 13,937,869 | 47,777,757 | 11,709,128 |
Net (loss) income per share of common stock, basic (in dollars per share) | $ (0.13) | $ 0.21 | $ (0.44) | $ (0.35) |
Change in fair value of warrant liability | $ (18,909,792) | |||
Interest on convertible debt | 28,891 | |||
Diluted net loss | $ (6,719,730) | $ 2,920,752 | $ (21,052,760) | $ (22,976,919) |
Common stock equivalents arising from stock options (in shares) | 20,608 | |||
Common stock equivalents arising from warrants (in shares) | 816,579 | |||
Common stock equivalents arising from convertible debt (in shares) | 756,376 | |||
Common stock equivalents (in shares) | 50,572,001 | 14,714,853 | 47,777,757 | 12,525,707 |
Net (loss) income per share of common stock, diluted (in dollars per share) | $ (0.13) | $ 0.20 | $ (0.44) | $ (1.83) |
Note 3 - Basis of Presentatio_5
Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details) - shares | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2018 | Sep. 30, 2017 | Sep. 30, 2018 | Sep. 30, 2017 | |
Anti-dilutive securities (in shares) | 34,516,809 | 16,529,812 | 34,516,809 | 3,212,188 |
Convertible Debt Securities [Member] | ||||
Anti-dilutive securities (in shares) | 213,879 | |||
Warrant [Member] | ||||
Anti-dilutive securities (in shares) | 31,303,012 | 14,003,608 | 31,303,012 | 447,721 |
Employee Stock Option [Member] | ||||
Anti-dilutive securities (in shares) | 3,213,797 | 2,521,605 | 3,213,797 | 2,545,989 |
Restricted Stock [Member] | ||||
Anti-dilutive securities (in shares) | 4,599 | 4,599 |
Note 4 - Accrued Expenses and_3
Note 4 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details) - USD ($) | Sep. 30, 2018 | Dec. 31, 2017 |
Accrued interest payable | $ 37,415 | |
Accrued Series A dividends | 1,062,314 | |
Accrued payroll and payroll related expenses | 618,131 | 312,221 |
Accrued professional fees | 80,051 | 122,711 |
Accrued clinical studies expenses | 47,688 | 63,350 |
Other accrued expenses | 70,750 | 30,840 |
Total | $ 816,620 | $ 1,628,851 |
Note 5 - Goodwill and Intangi_3
Note 5 - Goodwill and Intangible Assets (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2018 | Sep. 30, 2017 | Sep. 30, 2018 | Sep. 30, 2017 | Dec. 31, 2017 | |
Goodwill, Impairment Loss | $ 4,186,050 | $ 4,186,050 | |||
Impairment of Intangible Assets (Excluding Goodwill), Total | 0 | 0 | 0 | 0 | |
RES-529 [Member] | |||||
Intangible Assets, Gross (Excluding Goodwill), Total | 8,600,000 | 8,600,000 | $ 8,600,000 | ||
Impairment of Intangible Assets (Excluding Goodwill), Total | $ 0 | $ 0 | $ 0 | $ 0 |
Note 5 - Goodwill and Intangi_4
Note 5 - Goodwill and Intangible Assets - Goodwill Rollforward (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2018 | Sep. 30, 2017 | Sep. 30, 2018 | Sep. 30, 2017 | |
Balance, carrying value of goodwill | $ 6,929,258 | |||
Impairment of goodwill | $ (4,186,050) | (4,186,050) | ||
Balance, carrying value of goodwill | $ 2,743,208 | $ 2,743,208 |
Note 6 - Convertible Preferre_3
Note 6 - Convertible Preferred Stock, Common Stock and Common Stock Warrants (Details Textual) - USD ($) | Jan. 22, 2018 | Jan. 31, 2018 | Sep. 30, 2018 | Sep. 30, 2017 | Sep. 30, 2018 | Sep. 30, 2017 |
Stock Issued During Period, Shares, Conversion of Convertible Securities | 8,306,278 | |||||
Common Stock Dividends, Shares | 1,032,219 | |||||
Stock Issued During Period, Shares, Make-whole Adjustment | 11,668,421 | |||||
Dividends, Make-whole Adjustment | $ 8,200,000 | $ 8,167,895 | ||||
Class of Warrant or Rights, Expired | 421,221 | |||||
Class of Warrant or Right, Exercised | 0 | |||||
Conversion From Series A Preferred Stock to Common Stock [Member] | ||||||
Conversion of Stock, Shares Issued | 21,006,918 | 21,006,918 | ||||
Warrants Issued in Connection with the January 2018 Offering [Member] | ||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 15,000,000 | 15,000,000 | ||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.80 | $ 0.80 | ||||
Class of Warrant or Right, Term | 5 years | |||||
Warrants Issued in Connection with the January 2018 Offering [Member] | Maximum [Member] | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1 | $ 1 | ||||
Option Warrants [Member] | ||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 2,250,000 | |||||
Additional Warrants [Member] | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.80 | |||||
Class of Warrant or Right, Granted | 1,970,625 | |||||
Underwriter Warrants [Member] | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1 | |||||
Underwriter Warrants [Member] | Maximum [Member] | ||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 750,000 | 750,000 | ||||
Class of Warrant or Right, Term | 5 years | |||||
January 2018 Offering [Member] | ||||||
Stock Issued During Period, Shares, New Issues | 15,000,000 | 15,000,000 | ||||
Proceeds from Issuance or Sale of Equity, Total | $ 10,800,000 | $ 10,800,000 | ||||
Stock Issued During Period, Shares, Issued for Services | 2,250,000 | |||||
January 2018 Offering [Member] | Additional Warrants [Member] | ||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 1,970,625 |
Note 6 - Convertible Preferre_4
Note 6 - Convertible Preferred Stock, Common Stock and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details) - $ / shares | Sep. 30, 2018 | Jan. 31, 2018 | Jan. 22, 2018 |
Common stock warrants, outstanding (in shares) | 31,303,012 | ||
Warrants issued before 2016 [Member] | |||
Common stock warrants, outstanding (in shares) | 26,500 | ||
Warrants issued before 2016 [Member] | Minimum [Member] | |||
Range of exercise price (in dollars per share) | $ 37.50 | ||
Warrants issued before 2016 [Member] | Maximum [Member] | |||
Range of exercise price (in dollars per share) | $ 49 | ||
Warrants Attached to Series A Convertible Preferred Stock [Member] | |||
Common stock warrants, outstanding (in shares) | 13,555,887 | ||
Range of exercise price (in dollars per share) | $ 2.22 | ||
Warrants Issued in Connection with the January 2018 Offering [Member] | |||
Common stock warrants, outstanding (in shares) | 17,720,625 | ||
Range of exercise price (in dollars per share) | $ 0.80 | $ 0.80 | |
Warrants Issued in Connection with the January 2018 Offering [Member] | Minimum [Member] | |||
Range of exercise price (in dollars per share) | 0.80 | ||
Warrants Issued in Connection with the January 2018 Offering [Member] | Maximum [Member] | |||
Range of exercise price (in dollars per share) | $ 1 |
Note 7 - Stock-based Compensa_3
Note 7 - Stock-based Compensation (Details Textual) - USD ($) | Jan. 01, 2018 | Sep. 30, 2018 | Sep. 30, 2017 | Sep. 30, 2018 | Sep. 30, 2017 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 660,000 | ||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $ 2,100,000 | $ 2,100,000 | |||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 5 years 73 days | ||||
Allocated Share-based Compensation Expense, Total | 327,396 | $ 292,501 | $ 971,832 | $ 973,950 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | 0 | 0 | |||
Non-employee Stock Options [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 0 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | $ 1,000 | 7,000 | $ 3,000 | $ 83,000 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance | 5,166 | 5,166 | |||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $ 2,000 | $ 2,000 | |||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 1 year 94 days | ||||
Employee Stock Option [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 660,000 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 0.86 | ||||
Allocated Share-based Compensation Expense, Total | $ 300,000 | $ 300,000 | $ 1,000,000 | 900,000 | |
Restricted Stock [Member] | |||||
Allocated Share-based Compensation Expense, Total | $ 6,000 | $ 9,000 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance | 0 | 0 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period | 3,066 | 4,599 | |||
Restorgenex Corporation 2015 Equity Incentive Plan [Member] | |||||
Percentage of Total Shares Eligible for Plan Reserve, On an Annual Basis | 4.00% | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized | 580,785 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 27,268 | 27,268 |
Note 7 - Stock-based Compensa_4
Note 7 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2018 | Sep. 30, 2017 | Sep. 30, 2018 | Sep. 30, 2017 | |
Stock-based compensation expense | $ 327,396 | $ 292,501 | $ 971,832 | $ 973,950 |
Research and Development Expense [Member] | ||||
Stock-based compensation expense | 16,202 | 14,333 | 48,848 | 81,737 |
General and Administrative Expense [Member] | ||||
Stock-based compensation expense | $ 311,194 | $ 278,168 | $ 922,984 | $ 892,213 |
Note 7 - Stock-based Compensa_5
Note 7 - Stock-based Compensation - Stock Option Activity (Details) | 9 Months Ended |
Sep. 30, 2018$ / sharesshares | |
Options outstanding, number (in shares) | shares | 2,555,989 |
Options outstanding, weighted-average exercise price (in dollars per share) | $ / shares | $ 7.32 |
Granted (in shares) | shares | 660,000 |
Granted, weighted-average exercise price (in dollars per share) | $ / shares | $ 1.02 |
Expired (in shares) | shares | (2,192) |
Expired, weighted-average exercise price (in dollars per share) | $ / shares | $ 17.10 |
Options outstanding, number (in shares) | shares | 3,213,797 |
Options outstanding, weighted-average exercise price (in dollars per share) | $ / shares | $ 6.02 |
Options outstanding, weighted-average remaining contractual life (Year) | 7 years 3 days |
Exercisable (in shares) | shares | 2,361,007 |
Exercisable, weighted-average exercise price (in dollars per share) | $ / shares | $ 7.09 |
Exercisable, weighted-average remaining contractual life (Year) | 6 years 127 days |
Note 7 - Stock-based Compensa_6
Note 7 - Stock-based Compensation - Fair Value Assumptions (Details) | 9 Months Ended | |
Sep. 30, 2018 | Sep. 30, 2017 | |
Expected term (Year) | 5 years 208 days | 6 years 10 days |
Risk-free interest rate | 2.40% | 2.00% |
Expected volatility | 114.70% | 114.90% |
Dividend yield |
Note 8 - Commitments and Cont_3
Note 8 - Commitments and Contingencies (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2018 | Sep. 30, 2017 | Sep. 30, 2018 | Sep. 30, 2017 | |
Research and Development Expense, Total | $ 1,169,810 | $ 1,759,305 | $ 4,386,491 | $ 3,946,420 |
Arrangement With Clinical Research Organization [Member] | ||||
Research and Development Expense, Total | 400,000 | 1,600,000 | ||
Prepaid Research and Development Expense | 300,000 | 300,000 | ||
Charlottesville, Virginia [Member] | Building [Member] | ||||
Operating Leases, Rent Expense, Net, Total | $ 28,000 | $ 28,000 | $ 84,000 | $ 80,000 |
Note 8 - Commitments and Cont_4
Note 8 - Commitments and Contingencies - Total Future Operating Lease Obligations (Details) | Sep. 30, 2018USD ($) |
2,018 | $ 28,260 |
2,019 | 114,409 |
2,020 | 116,464 |
2,021 | 118,519 |
2,022 | 39,735 |
Total | $ 417,387 |